Advancing Clinical Research in Indonesia: Equilab International, RSUI, and Daewoong Pharmaceutical Collaborate on Diabetes Multiregional Clinical Trials
Depok, November 11, 2026 – Equilab International, Rumah Sakit Universitas Indonesia (RSUI) or also known as The University of Indonesia Hospital, and Daewoong Pharmaceutical, officially signed a Clinical Trial Agreement (CTA) for the global diabetes study. The signing ceremony was held at RSUI, marking the establishment of a research collaboration between the three organizations. The agreement formalizes the collaboration between RSUI as the clinical trial site, Daewoong Pharmaceutical as the study sponsor, and Equilab International as the Contract Research Organization (CRO) supporting the study.
The signing ceremony was attended by representatives from all three organizations, including Ronal Simanjuntak, S.Si, Apt., M.M, President Director of Equilab International; dr. Tommy Dharmawan, Sp.B.T.KV., Ph.D., Operational Director of RSUI; and dr. Stella Melisa, Chief Medical and Development Officer - Daewoong Pharmaceutical Indonesia. The event was also attended by dr. Livy Bonita Pratisthita, Sp.PD, Subsp. EMD(K), who will serve as the Principal Investigator.
During the ceremony, dr. Tommy Dharmawan, Sp.B.T.KV., Ph.D., Operational Director of RSUI, highlighted the significant potential for clinical trial development and expressed his hopes for a successful collaboration among the three organizations.
"We see great potential in clinical research, and we hope RSUI can become a reliable research site for Daewoong Pharmaceutical and Equilab International. Through this collaboration, we look forward to building strong cooperation and achieving positive study outcomes while ensuring that the research is conducted in accordance with the required standards," he stated.
Representing Equilab International, Ronal Simanjuntak, President Director of Equilab International, emphasized Equilab's experience in supporting clinical research including experiences managing global trials. He also highlighted the importance of maintaining three key aspects throughout clinical trial execution: quality, timelines, and cost.
"As one of Indonesia's pioneering Contract Research Organizations and the first CRO in the country, Equilab has been committed to supporting both local and global clinical research. In every study, we prioritize quality, timelines, and cost as key elements of successful clinical trial execution. We sincerely hope that all three parties can work closely together to uphold these priorities and achieve the best possible outcomes for this study," he added.
Chief Medical and Development Officer of Daewoong Pharmaceutical, Dr. Stella Melisa emphasized that the signing of the Clinical Trial Agreement represents Daewoong Pharmaceutical’s commitment to advancing clinical research in Indonesia, with each party playing a complementary role in the study.
“Through continued collaboration, scientific excellence, and a shared commitment, we sincerely hope that this partnership will bring meaningful benefits to patients and contribute to the advancement of Indonesia’s healthcare and clinical research landscape,” she stated.
As the leading CRO in Indonesia, Equilab International is committed to facilitating the successful conduct of the global diabetes clinical trial in Indonesia in accordance with global research standards. Through its involvement in global clinical trials, Equilab aims to bring more international research opportunities to Indonesia while contributing to the development of the country's clinical research capabilities.